Cingulate Inc. (CING) - Latest Market Data

Price & Market Data

Price: $4.44

Daily Change: -$0.30 / 6.76%

Daily Range: $4.27 - $4.95

Market Cap: $59,343,816

Daily Volume: 486,279

Performance Metrics

1 Week: 8.35%

1 Month: -21.91%

3 Months: -22.30%

6 Months: 35.76%

1 Year: 37.35%

YTD: 8.35%

About Cingulate Inc. (CING)

Get quick and reliable data for Cingulate Inc. (CING). Price: 4.44, daily change: -$0.30 / 6.76%. Market cap: 59,343,816. Performance across all periods for informed decisions.

Company Details

Employees: 14

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Selected stocks

Yimutian Inc. (YMT)

eHealth, Inc. (EHTH)

Marti Technologies, Inc. (MRT)

Celularity Inc. (CELU)